FDA Releases Final Guidance on Review of Drug Master Files Ahead of Generic Drug Submissions

Summary

The FDA has released a final guidance on reviewing drug master files six months prior to certain generic drug submissions, as part of the Generic Drug User Fee Amendments (GDUFA) III program.